# Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Source: https://onco.cc/trials/nct06747845/  
OnCo record `nct06747845` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of niraparib and ipilimumab in pancreatic cancer, run by Abramson Cancer Center at Penn Medicine, now recruiting.

## Summary

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy is a phase 2, randomised interventional study registered as NCT06747845 by Abramson Cancer Center at Penn Medicine, with a registry enrolment figure of 68 participants, started 2025-05-07 and due to reach its primary completion in 2028-06. Interventions recorded: Niraparib; FOLFIRI; Ipilimumab. Conditions listed: Pancreatic Adenocarcinoma Metastatic. Primary outcome: Progression-free survival (PFS) in the experimental arm. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with metastatic disease". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: ParpVax2
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06747845
- Phase: 2
- Setting: ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy
- Sponsor: Abramson Cancer Center at Penn Medicine
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT06747845: https://clinicaltrials.gov/study/NCT06747845

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Niraparib](https://onco.cc/drugs/niraparib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06747845.json